{
    "clinical_study": {
        "@rank": "33344", 
        "arm_group": {
            "arm_group_label": "Treatment (radiation therapy)", 
            "arm_group_type": "Experimental", 
            "description": "Patients undergo wide local excision breast surgery and SFRT over 60-100 minutes once negative margins are obtained."
        }, 
        "brief_summary": {
            "textblock": "This phase II trial studies how well radiation therapy works in treating post-menopausal\n      women with early stage breast cancer undergoing surgery. Radiation therapy uses high energy\n      x rays to kill tumor cells. This may be an effective treatment for breast cancer."
        }, 
        "brief_title": "Radiation Therapy in Treating Post-Menopausal Women With Early Stage Breast Cancer Undergoing Surgery", 
        "condition": [
            "Ductal Breast Carcinoma in Situ", 
            "Estrogen Receptor-negative Breast Cancer", 
            "Estrogen Receptor-positive Breast Cancer", 
            "HER2-negative Breast Cancer", 
            "Invasive Ductal Breast Carcinoma", 
            "Lobular Breast Carcinoma in Situ", 
            "Progesterone Receptor-positive Breast Cancer", 
            "Stage I Breast Cancer", 
            "Stage II Breast Cancer", 
            "Stage IIIA Breast Cancer", 
            "Stage IIIC Breast Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Breast Neoplasms", 
                "Carcinoma", 
                "Carcinoma in Situ", 
                "Carcinoma, Intraductal, Noninfiltrating", 
                "Carcinoma, Ductal, Breast", 
                "Carcinoma, Lobular"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVE:\n\n      I. For select patients with early stage breast cancer undergoing wide local excision\n      followed by single fraction radiation therapy (SFRT), we will evaluate rates of\n      observer-rated toxicity, cosmetic outcomes and patient satisfaction, objective measures of\n      toxicity and quality of life as well as delivery of intended dose.\n\n      SECONDARY OBJECTIVE:\n\n      I. Locoregional control reported at five years.\n\n      OUTLINE:\n\n      Patients undergo wide local excision breast surgery and SFRT over 60-100 minutes once\n      negative margins are obtained.\n\n      After completion of study treatment, patients are followed at 1 week, 1 month, 3 months, and\n      then every 6 months for 2 years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Core needle biopsy (e.g. Mammotome, core, stereotactic, ultrasound guided) showing\n             invasive mammary cancer (with or without concomitant ductal carcinoma or lobular\n             carcinoma in situ) or ductal carcinoma in situ; acceptable histologic types of\n             invasive mammary cancer include ductal, tubular, mucinous, papillary, cribriform and\n             \"NOS\"(not otherwise specified); invasive lobular cancer is excluded\n\n          -  Age >= 50 years and postmenopausal with no menses for at least one year prior to\n             study enrollment\n\n          -  Age > 70 years with invasive breast cancer clinical size =< 3cm OR Age 50 - 70 years\n             with invasive breast cancer clinical size =< 1.5 cm OR Age >= 50 years and\n             postmenopausal with any grade ductal carcinoma in situ (DCIS) clinical extent =< 1.5\n             cm (clinical tumor size will be determined by pre-operative breast\n             imaging-mammography, ultrasound and/or magnetic resonance imaging; in cases of\n             multiple measurements, the largest recorded single dimension will be used to\n             determine eligibility)\n\n          -  Hormone receptor status\n\n               -  Estrogen or progesterone receptor positive or\n\n               -  Estrogen and progesterone receptor negative and clinical tumor size =< 1.0 cm\n\n          -  Human epidermal growth factor receptor 2 (HER2)/neu negative on the core biopsy\n             analysis defined as 0 or 1+ by immunohistochemistry or not amplified by fluorescent\n             in situ hybridization analysis\n\n          -  Tumor >= 0.5cm from skin as defined by breast ultrasound\n\n          -  Unicentric tumor\n\n          -  Axillary lymph nodes negative by pre-operative physical examination in all cases and\n             pathologic examination from surgery for invasive disease\n\n          -  Negative surgical margins, defined as no margin-labeling ink on tumor cells from\n             margin evaluation\n\n        Exclusion Criteria:\n\n          -  Initial core biopsy showing invasive lobular cancer\n\n          -  Estrogen receptor and progesterone receptor negative tumor with clinical size > 1 cm\n\n          -  Any Her 2+ breast cancer (immunohistochemistry 3+; or amplified by fluorescence in\n             situ hybridization [FISH])\n\n          -  Cancer in a patient with a known inherited susceptibility mutation in breast cancer\n             (BRCA)1 or BRCA2\n\n          -  Multicentric breast cancer (two foci of known cancer in the breast separated by\n             greater than 5cm, or in separate quadrants\n\n          -  Clinically or pathologically positive axillary lymph nodes\n\n          -  Any prior breast cancer\n\n          -  Prior breast radiation therapy"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "82", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 23, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01754519", 
            "org_study_id": "I 108907", 
            "secondary_id": [
                "NCI-2009-01568", 
                "I 108907", 
                "P30CA016056"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment (radiation therapy)", 
                "description": "Undergo wide local excision breast surgery", 
                "intervention_name": "therapeutic conventional surgery", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "Treatment (radiation therapy)", 
                "description": "Undergo SFRT", 
                "intervention_name": "radiation therapy", 
                "intervention_type": "Radiation", 
                "other_name": [
                    "irradiation", 
                    "radiotherapy", 
                    "therapy, radiation"
                ]
            }, 
            {
                "arm_group_label": "Treatment (radiation therapy)", 
                "description": "Ancillary studies", 
                "intervention_name": "quality-of-life assessment", 
                "intervention_type": "Procedure", 
                "other_name": "quality of life assessment"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "February 25, 2014", 
        "location": {
            "contact": {
                "email": "ASKRPCI@roswellpark.org", 
                "last_name": "Roswell Park", 
                "phone": "877-275-7724"
            }, 
            "facility": {
                "address": {
                    "city": "Buffalo", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "14263"
                }, 
                "name": "Roswell Park Cancer Institute"
            }, 
            "investigator": {
                "last_name": "David M. Mattson", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase II Trial of Single Fraction Radiation Therapy (SFRT) at Roswell Park Cancer Institute for Select Patients With Early Stage Breast Cancer", 
        "overall_official": {
            "affiliation": "Roswell Park Cancer Institute", 
            "last_name": "David Mattson", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Toxicity will be assessed by the National Cancer Institute (NCI) Common Toxicity Criteria (CTC) v 3.0.", 
                "measure": "Number of patients with adverse events as a measure of safety and tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 2 years"
            }, 
            {
                "description": "Will be rated by patients using the POST-B, the Functional Assessment of Chronic Illness Therapy (FACIT), and the Skindex-16.", 
                "measure": "Quality-of-life assessments", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years"
            }, 
            {
                "description": "Will measure differences in the cosmetic size, shape, or texture of the breast. Cosmesis will be graded according to the Baker Scale. Patient reported cosmesis will also be evaluated using the Ontario Clinical Oncology Breast Cancer Questionnaire.", 
                "measure": "Cosmetic differences in the treated breast", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01754519"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Locoregional control will be calculated with confidence interval estimates and will be compared to historical control rates.", 
                "measure": "Locoregional control rate", 
                "safety_issue": "No", 
                "time_frame": "At 5 years"
            }, 
            {
                "description": "The overall survival will be analyzed using Kaplan-Meier method.", 
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "Up to 5 years"
            }, 
            {
                "description": "The disease specific survival will be analyzed using Kaplan-Meier method.", 
                "measure": "Disease specific survival", 
                "safety_issue": "No", 
                "time_frame": "Up to 5 years"
            }
        ], 
        "source": "Roswell Park Cancer Institute", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Roswell Park Cancer Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}